HeartFlow Receives Clearance For Noninvasive Testing Of Coronary Artery Disease
Executive Summary
HeartFlow recently gained FDA go-ahead for its FFR-CT technology, a first-of-its-kind, noninvasive diagnostic test that allows physicians to assess blood flow in patients with coronary artery disease. With more than 25 million patients who could potentially benefit from this test in the US, EU, and Japan alone, the market potential for this technology is enormous.
You may also be interested in...
HeartFlow Cleared To Launch Non-Invasive FFR Software In U.S.
FDA granted market access to HeartFlow's fractional flow reserve-computed tomography software, the first non-invasive fractional flow reserve technology for assessing coronary artery blockages.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.